The codirector of interventional neuroradiology and vice-chief of the department of neuroscience at Baptist Health Miami Neuroscience Institute provided clarity on the complexities with treating subarachnoid hemorrhage on an individual case basis. [WATCH TIME: 4 minutes]
Here's some of what is coming soon to NeurologyLive® this week.
Over a 4-year follow-up, SARA progression was substantially linear. Age at evaluation also influenced the speed of SARA progression, while disease duration did not improve the prediction of the statistical model.
The professor of neurology at NYU Langone Grossman School of Medicine discussed the Women in Neurology session she gave at IFN 2023, where women shared their experiences from their medical careers. [WATCH TIME: 3 minutes]
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is epilepsy and seizure disorders.
Years of genetic research has uncovered more about the underpinnings of limb-girdle muscular dystrophy, leading to potential disease-modifying therapies in the near future.
In honor of Limb-Girdle Muscular Dystrophy Awareness Day, held September 30, 2023, get caught up on some of the latest news in LGMD, with data updates and expert insights all in one place from the NeurologyLive® team.
Neurology News Network for the week ending September 30, 2023. [WATCH TIME: 4 minutes]
The AI-based SOMNUM technology uses diagnostic algorithms based on multi-channel/time series sleep biosignal data to deliver fast, accurate diagnostic information for providers.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 29, 2023.
The professor of neurology and translational neuroscientist at Ludwig-Maximillian’s University Munich detailed the logic behind the ORION study, a new trial assessing AMX0035, an approved therapy for ALS, in patients with progressive supranuclear palsy. [WATCH TIME: 4 minutes]
In a phase 3 setting, the 2-component therapy showed positive trends or clinically meaningful improvements on motor and respiratory functions compared with previously approved enzyme replacement therapy.
The associate professor of neurology at NYU Grossman School of Medicine discussed her talk at IFN 2023 on advancements in epilepsy treatments, highlighting new medications and surgical options. [WATCH TIME: 3 minutes]
Erin Longbrake, MD, PhD, associate professor of neurology at Yale School of Medicine, discussed the importance of understanding rare autoimmune disorders to effectively design clinical trials and treatment strategies, especially for heterogeneous conditions like NMOSD and MOGAD.
Over a 4-week treatment period, patients in both Lu AG09222 groups experienced about 2 fewer migraine days per month compared with placebo.
The professor of neurology and resident program director at MedStar Georgetown University Hospital discussed how Parkinson disease motor fluctuations are managed amid new, novel technologies incorporated in the field. [WATCH TIME: 4 minutes]
As part of our monthly clinician spotlight, NeurologyLive® highlighted neueomuscular expert Peter Kang, MD, director of the Paul and Sheila Wellstone Muscular Dystrophy Center and professor of neurology at the University of Minnesota.
The codirector of the Mount Sinai Epilepsy Program at the Icahn School of Medicine at Mount Sinai talked about the Women in Neurology and Leadership session she spoke in at IFN 2023. [WATCH TIME: 3 minutes]
Patients who self-identified as Black and were living in less affluent neighborhoods were less likely to be seen in one large memory clinic as well as have more severe dementia at initial visit.
After deliberating, the FDA committee expressed concerns about the mechanism of action of NurOwn, manufacturing details, and consistency of data.
By targeting tau-ack280, ADEL-Y01 inhibits tau aggregation and propagation, and promotes microglial tau clearance.
The director of the Center for Brain Health and Alzheimer Prevention Clinic at Florida Atlantic University provided perspectives on the multimodal, multitargeted approach needed to treat Alzheimer disease. [WATCH TIME: 5 minutes]
The phase 3 SYMPHONY trial assessing AXS-12, a selective norepinephrine reuptake inhibitor for narcolepsy, was initially expected in the third quarter of 2023.
The professor of neurology at Stony Brook University Medical Center discussed the progress observed in the field of multiple sclerosis and the lack of effective treatments for progressive forms of the disease. [WATCH TIME: 3 minutes]
The chief of the Movement Disorders Division at Mass General Hospital provided context on the goals behind the research careers reimagined course at the recently concluded ANA Annual Meeting.
Coya Therapeutics expects to release data from the biomarker analyses of COYA 302 and publish the full results from the trial in a peer-reviewed journal in the second half of the year.
Although research supports the use of physical therapy as an effective treatment for Parkinson disease, implementation factors including type, timing, frequency, and durability of outcomes remain mainly untouched.
The associate professor of neurology at Vanderbilt University Medical Center discussed the progress in stroke care, focusing on ischemic strokes and cerebral hemorrhages, and their connection with vascular diseases and cognitive disorders. [WATCH TIME: 3 minutes]
Between ages 65 to 69, gene carriers of APOE ε4 could detect an average of about 3.2 of the smells presented, compared with about 3.9 smells for noncarriers of the gene variant.
The associate professor of neurology at Yale School of Medicine discussed the differentiation of neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein -associated disease from multiple sclerosis at IFN 2023. [WATCH TIME: 5 minutes]
